Table 3.
Effect of diacerein on inflammatory markers at end of trial.
| Diacerein (n = 35) | Placebo (n = 36) | RR (95% CI)∗ | P value | |
|---|---|---|---|---|
| α − Tumor necrosis factor ≤ 1.46 (pg/mL) | 23 (65.7) | 14 (38.9) | 1 (1.04–2.1) | 0.03 |
| Interleukin − 1β > 1.23 | 8 (22.9) | 15 (41.7) | 0.7 (0.4–1.3) | 0.3 |
| Interleukin − 6 ≤ 10.7 | 17 (48.6) | 14 (38.9) | 1.4 (0.9–2.2) | 0.19 |
| Interleukin − 8 ≤ 29.53 | 6 (17.1) | 2 (5.6) | 3.1 (0.7–14.8) | 0.15 |
| Interleukin − 10 ≤ 5.25 | 10 (28.6) | 5 (13.9) | 1.8 (0.7–4.6) | 0.19 |
| Leptin ≤ 10.3 | 11 (31.4) | 6 (16.7) | 1.4 (0.8–2.6) | 0.3 |
| Selectin ≤ 53.4 | 6 (17.1) | 16 (44.4) | 0.6 (0.3–1.2) | 0.14 |
| Adiponectin ≤ 11.8 | 15 (42.9) | 17 (47.2) | 0.8 (0.5–1.2) | 0.4 |
Data expressed as n (%) and relative risk (95%CI). ∗Relative risk adjusted for baseline values of the inflammatory markers.